PMID: 9194148May 1, 1997Paper

Ritanserin administration potentiates amphetamine-stimulated dopamine release in the rat prefrontal cortex

Progress in Neuro-psychopharmacology & Biological Psychiatry
E A Pehek, Y Bi

Abstract

1. Administration of serotonin 5-HT2 receptor antagonists increases the basal release of dopamine in the mesocorticolimbic pathway. 2. Treatment with dopamine D2 receptor antagonists increases impulse-dependent basal dopamine release in the nigrostriatal pathway. D2 antagonists also potentiate carrier-mediated increases in DA efflux from this pathway. 3. The present study compared the effects of a 5-HT2A/C antagonist (ritanserin) and a D2 antagonist (haloperidol) on carrier-mediated (amphetamine-induced) DA release in the mesocortical system. 4. In vivo microdialysis was used to recover extracellular fluid from the medial prefrontal cortex of conscious rats. Samples were then assayed for dopamine content by HPLC with electrochemical detection. Haloperidol or ritanserin were administered systemically (i.p.) 30 min before d-amphetamine (5.0 mg/kg i.p.). 5. Results demonstrated that 5.0 mg/kg ritanserin, but not 1.0 mg/kg, potentiated amphetamine-induced DA release in the prefrontal cortex. Similar to previous findings in the striatum, haloperidol (1.0 mg/kg) also augmented amphetamine-stimulated DA efflux in the cortex. 6. These results suggest that 5-HT2 and D2 receptor antagonists increase impulse-mediated dopamine release in t...Continue Reading

References

May 1, 1992·Journal of Neurochemistry·B K Yamamoto, S Davy
Feb 1, 1988·Journal of Neurochemistry·S P ButcherG W Arbuthnott
Jun 19, 1989·Neuroscience Letters·A Imperato, L Angelucci
May 30, 1989·European Journal of Pharmacology·E CarboniG Di Chiara
Jan 1, 1982·Comparative Biochemistry and Physiology. C: Comparative Pharmacology·R J Walker, C J Roberts
Aug 1, 1982·Journal of Neurochemistry·S KatoK Negishi
Aug 1, 1982·Biochemical Pharmacology·N Y Liang, C O Rutledge
Aug 10, 1993·European Journal of Pharmacology·E A PehekB K Yamamoto

❮ Previous
Next ❯

Citations

Dec 3, 1999·Progress in Neuro-psychopharmacology & Biological Psychiatry·T KurokiN Tashiro
Jan 13, 2000·Progress in Neuro-psychopharmacology & Biological Psychiatry·E M Nakamura-PalaciosC F Gomes
Dec 1, 2015·Pharmacology & Therapeutics·Giuseppe Di Giovanni, Philippe De Deurwaerdère
Mar 26, 2016·Progress in Neurobiology·Philippe De Deurwaerdère, Giuseppe Di Giovanni
Oct 20, 2006·Pharmacology & Therapeutics·K D Alex, E A Pehek
Mar 25, 2014·Pharmacology & Therapeutics·Peter H HutsonAshwin A Patkar
Aug 15, 2002·CNS Drug Reviews·Franco BorsiniStephan Pollentier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.